Cardiff Lexington Announces Third Quarter 2026 Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Lexington (CDIX) reported third-quarter revenue of $1,912,179, down from the comparable prior-year quarter, as its net loss widened. Revenue was $3,058,740 a year earlier; net loss increased to $3,206,551 from $1,144,299. For the nine months ended September 30, 2026, revenue fell to $6,294,016 from $8,763,314, and net loss widened to $8,777,531 from $2,821,471.
The company attributed lower nine-month revenue primarily to fewer procedures and lower patient-claim settlement realization, and said working capital constraints limited opportunities. Cash reached $584,319, while current liabilities were $28,506,106 against current assets of $24,219,296. Cardiff accepted financing and equity term sheets for its planned acquisition, but negotiations exceeded the anticipated November 16 timeline. Execution remains subject to satisfactory due diligence and final financing; Cardiff expects further progress in December, with no definitive execution date.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointAcquisition financing advanced with accepted financing and equity term sheets; related due diligence, underwriting and documentation continue.
- Moderate pointStockholders' deficit narrowed to $283,512 from $2,469,661 at December 31, 2025.
- Moderate pointRelated-party accrued expenses fell to $568,048 from $4,645,826 at December 31, 2025.
- Minor pointCash increased to $584,319 at September 30, 2026, from $318,535 at December 31, 2025.
- Minor pointCost of sales declined to $875,420 for Q3 and $2,756,887 for nine months, versus $1,149,161 and $3,317,943.
- Minor pointQ3 selling, general and administrative expenses fell to $1,203,211 from $1,224,350 a year earlier.
Negative
- Major pointQ3 revenue fell to $1,912,179 from $3,058,740 a year earlier.
- Major pointQ3 net loss widened to $3,206,551 from $1,144,299 a year earlier.
- Major pointCurrent liabilities of $28,506,106 exceeded current assets of $24,219,296 at September 30, 2026.
- Major pointLine of credit increased to $23,439,491 from $17,209,908 at December 31, 2025.
- Moderate pointWorking capital constraints limited opportunities, the company said; fewer procedures and lower settlement realization primarily reduced nine-month revenue.
- Moderate pointAcquisition execution remains pending, subject to satisfactory due diligence and final financing arrangements.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Anticipated November 16 acquisition timeline extended; Cardiff expects December progress but has no definitive execution date.
- Moderate pointCommon shares outstanding rose to 17,026,827 from 13,701,698 at December 31, 2025, diluting existing holders.
- Moderate pointQ3 gross profit fell to $1,036,759 from $1,909,579 a year earlier.
- Moderate pointQ3 operating loss reached $536,666, versus operating income of $643,279 a year earlier.
- Moderate pointInterest expense increased to $2,468,536 for Q3 and $6,516,692 for nine months, versus $1,765,528 and $4,594,714.
- Moderate pointStock compensation expense increased to $369,981 for Q3 and $1,401,116 for nine months, versus $41,188 and $138,688.
- Moderate pointNine-month selling, general and administrative expenses rose to $3,727,402 from $3,492,310 a year earlier.
- Moderate pointQ3 EBITDA turned negative at $715,266, versus positive $621,991; EBITDA excludes interest, taxes, depreciation and amortization.
- Moderate pointRelated-party long-term notes payable increased to $350,000 from zero at December 31, 2025.
16 minor points
- Minor pointNine-month revenue fell to $6,294,016 from $8,763,314 a year earlier.
- Minor pointNine-month net loss widened to $8,777,531 from $2,821,471 a year earlier.
- Minor pointNine-month gross profit fell to $3,537,129 from $5,445,371 a year earlier.
- Minor pointNine-month operating loss reached $1,592,468, versus operating income of $1,796,890 a year earlier.
- Minor pointDerivative liability losses were $50,242 for Q3 and $493,014 for nine months, versus zero in both prior-year periods.
- Minor pointDebt-discount amortization was $22,516 for Q3 and $56,847 for nine months, versus zero in both prior-year periods.
- Minor pointDebt settlement loss of $16,498 affected both Q3 and nine-month results, versus zero a year earlier.
- Minor pointPenalties and fees increased to $5,500 for both Q3 and nine months, versus $1,500 in each prior-year period.
- Minor pointNine-month EBITDA turned negative at $2,202,913, versus positive $1,778,133 a year earlier.
- Minor pointQ3 adjusted EBITDA turned negative at $278,545, versus positive $663,179 a year earlier; this is non-GAAP.
- Minor pointNine-month adjusted EBITDA turned negative at $292,285, versus positive $1,916,821 a year earlier; this is non-GAAP.
- Minor pointQ3 further-adjusted EBITDA was negative $102,686, versus positive $776,615, excluding other non-recurring costs; this is non-GAAP.
- Minor pointNine-month further-adjusted EBITDA fell to $170,855 from $2,100,012, excluding other non-recurring costs; this is non-GAAP.
- Minor pointOffering costs of $106,593 affected both Q3 and nine-month results.
- Minor pointNine-month acquisition costs rose to $274,362 from $171,515; Q3 costs fell to $56,558 from $113,436.
- Minor pointScaling and restructuring business growth costs increased to $12,708 for Q3 and $82,185 for nine months, versus $0 and $11,676.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, KY / ACCESS Newswire / November 16, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 with the U.S. Securities and Exchange Commission.
Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Through the first nine months of 2026, we have stayed focused on our long-term strategy of building Nova Ortho and Spine into a leading healthcare network and expanding access to high-quality care for a patient population that has long been underserved. Revenue was lower than in the prior-year period primarily due to fewer procedures and a lower implicit realization rate on patient case claim settlements. While demand for our services in the markets we serve remains high, working capital constraints has limited our ability to capitalize on opportunities. That said, we retained healthy gross margins of
"To that end, we continue to make meaningful progress toward the execution of a definitive acquisition agreement under our previously announced letter of intent. Due diligence and negotiations of definitive transaction documents remain ongoing. Importantly, we have received and accepted financing and equity term sheets and are actively advancing the related due diligence, underwriting, and documentation processes. While these additional steps have extended the previously anticipated November 16 timeline, we remain focused on completing the necessary requirements and advancing the transaction toward a definitive agreement, subject to satisfactory due diligence, final financing arrangements, and other customary conditions. We currently anticipate further progress in December, although no definitive execution date has been established."
"In previous years, the Cardiff Lexington model has proven its ability to deliver strong returns on invested capital. Our priorities now are restoring that performance at scale, putting a stronger capital structure behind it and building durable value for our shareholders. We appreciate our shareholders' patience and support," Mr. Cunningham concluded.
Financial tables are below, and the Company's Quarterly Report on Form 10-Q is available on the SEC's website at www.sec.gov and on the Investor Relations section of the Company's website.
Conference Call
Cardiff Lexington will hold a conference call and webcast for investors today, November 16, 2026, at 11:00 a.m. Eastern Time.
Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 937760. The call and the accompanying slide deck will also be webcast at:
https://www.webcaster5.com/Webcast/Page/3131/54813
An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until Monday, November 30, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 54813 to access the replay.
-----
About Cardiff Lexington Corporation:
Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care.
The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.
FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.
Use of Non-GAAP Financial Measures
Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.
Cardiff Lexington Investor Relations
investorrelations@cardifflexington.com
(800) 628-2100 ext. 705
or
IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(UNAUDITED)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Total revenue | $ | 1,912,179 | $ | 3,058,740 | $ | 6,294,016 | $ | 8,763,314 | ||||||||
Total cost of sales | 875,420 | 1,149,161 | 2,756,887 | 3,317,943 | ||||||||||||
Gross profit | 1,036,759 | 1,909,579 | 3,537,129 | 5,445,371 | ||||||||||||
Operating expenses | ||||||||||||||||
Depreciation expense | 233 | 762 | 1,079 | 4,890 | ||||||||||||
Loss on disposal of fixed assets | 0 | 0 | 0 | 12,593 | ||||||||||||
Stock compensation expense | 369,981 | 41,188 | 1,401,116 | 138,688 | ||||||||||||
Selling, general and administrative | 1,203,211 | 1,224,350 | 3,727,402 | 3,492,310 | ||||||||||||
Total operating expenses | 1,573,425 | 1,266,300 | 5,129,597 | 3,648,481 | ||||||||||||
(Loss) income from operations | (536,666 | ) | 643,279 | (1,592,468 | ) | 1,796,890 | ||||||||||
Other (expense) income : | ||||||||||||||||
Other income (expense) | (106,593 | ) | (20,550 | ) | (96,512 | ) | (22,147 | ) | ||||||||
Loss on settlement of debt | (16,498 | ) | 0 | (16,498 | ) | 0 | ||||||||||
Penalties and fees | (5,500 | ) | (1,500 | ) | (5,500 | ) | (1,500 | ) | ||||||||
Derivative liability loss on issuance and change in fair value | (50,242 | ) | 0 | (493,014 | ) | 0 | ||||||||||
Interest expense | (2,468,536 | ) | (1,765,528 | ) | (6,516,692 | ) | (4,594,714 | ) | ||||||||
Amortization of debt discounts | (22,516 | ) | 0 | (56,847 | ) | 0 | ||||||||||
Total other expense | (2,669,885 | ) | (1,787,578 | ) | (7,185,063 | ) | (4,618,361 | ) | ||||||||
Net loss | $ | (3,206,551 | ) | $ | (1,144,299 | ) | $ | (8,777,531 | ) | $ | (2,821,471 | ) | ||||
*Shares outstanding for the three and nine months ended September 30, 2025 have been restated for the 1-for-3 reverse stock split effective January 12, 2026. See Note 1. Summary of Significant Accounting Policies.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2026 (UNAUDITED) AND DECEMBER 31, 2025
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash | $ | 584,319 | $ | 318,535 | ||||
Accounts receivable, net | 23,400,209 | 22,070,954 | ||||||
Prepaid and other current assets | 234,768 | 203,876 | ||||||
Total current assets | 24,219,296 | 22,593,365 | ||||||
Property and equipment, net | 1,874 | 2,953 | ||||||
Land | 540,000 | 540,000 | ||||||
Goodwill | 5,666,608 | 5,666,608 | ||||||
Right of use - assets | 75,266 | 214,858 | ||||||
Due from related party | 4,979 | 4,979 | ||||||
Other assets | 74,789 | 64,182 | ||||||
Total assets | $ | 30,582,812 | $ | 29,086,945 | ||||
LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' DEFICIT | ||||||||
Current liabilities | ||||||||
Accounts payable and accrued expense | $ | 1,707,311 | $ | 1,760,765 | ||||
Accrued expenses - related parties | 568,048 | 4,645,826 | ||||||
Accrued interest | 834,801 | 707,574 | ||||||
Right of use - operating lease liability | 75,728 | 178,524 | ||||||
Notes payable - current portion | 15,689 | 125,774 | ||||||
Notes payable related parties - current portion | 1,085,703 | 1,085,703 | ||||||
Line of credit | 23,439,491 | 17,209,908 | ||||||
Convertible notes payable, net of debt discounts of respectively | 240,205 | 118,295 | ||||||
Derivative liability | 539,130 | 0 | ||||||
Total current liabilities | 28,506,106 | 25,832,369 | ||||||
Other liabilities | ||||||||
Operating lease liability - long term | 0 | 42,976 | ||||||
Notes payable | 136,289 | 138,773 | ||||||
Notes payable related parties | 350,000 | 0 | ||||||
Total liabilities | 28,992,395 | 26,014,118 | ||||||
Mezzanine equity | ||||||||
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, and outstanding at September 30, 2026 and December 31, 2025, respectively | 0 | 3,802,010 | ||||||
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, issued and outstanding at September 30 2026 and December 31, 2025, respectively | 1,873,929 | 1,740,478 | ||||||
Total Mezzanine Equity | 1,873,929 | 5,542,488 | ||||||
Stockholders' deficit | ||||||||
Series A-1 Preferred Stock - 2 shares authorized, 2025 | 500 | 0 | ||||||
Series F-1 Preferred Stock - 50,000 shares authorized, value December 31, 2025 | 15,500 | 15,500 | ||||||
Series L Preferred Stock - 400,000 shares authorized, value December 31, 2025 | 1,277,972 | 1,277,972 | ||||||
Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, par value, stated value September 30, 2026 and December 31, 2025, respectively | 4,185,670 | 0 | ||||||
Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, par value, stated value of outstanding at September 30, 2026 and December 31 2025, respectively | 4,602,107 | 4,271,512 | ||||||
Common Stock; 300,000,000 shares authorized, 13,701,698 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 17,026 | 13,702 | ||||||
Additional paid-in capital | 78,860,451 | 72,021,848 | ||||||
Unearned stock compensation | (125,065 | ) | (579,215 | ) | ||||
Accumulated deficit | (89,117,673 | ) | (79,490,980 | ) | ||||
Total stockholders' deficit | (283,512 | ) | (2,469,661 | ) | ||||
Total liabilities, mezzanine equity and stockholders' deficit | $ | 30,582,312 | $ | 29,086,945 | ||||
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026, AND 2025
(Unaudited)
The following table reconciles Net income (loss) before discontinued operations (a GAAP financial measure) to EBITDA and Adjusted EBITDA (non-GAAP financial measures)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
EBITDA (1) | ||||||||||||||||
Net loss before discontinued operations | $ | (3,206,551 | ) | $ | (1,144,299 | ) | $ | (8,777,531 | ) | $ | (2,821,471 | ) | ||||
Add: | ||||||||||||||||
Interest | 2,468,536 | 1,765,528 | 6,516,692 | 4,594,714 | ||||||||||||
Taxes | 0 | 0 | 0 | 0 | ||||||||||||
Depreciation | 233 | 762 | 1,079 | 4,890 | ||||||||||||
Amortization | 22,516 | 0 | 56,847 | 0 | ||||||||||||
EBITDA (1) | $ | (715,266 | ) | $ | 621,991 | $ | (2,202,913 | ) | $ | 1,778,133 | ||||||
Adjusted EBITDA (2) | ||||||||||||||||
EBITDA | $ | (715,266 | ) | $ | 621,991 | $ | (2,202,913 | ) | $ | 1,778,133 | ||||||
Add: | ||||||||||||||||
Derivative liability loss on issuance and change in fair value | 50,242 | 0 | 493,014 | 0 | ||||||||||||
Loss on settlement of debt | 16,498 | 0 | 16,498 | 0 | ||||||||||||
Stock compensation expense for shares issued | 369,981 | 41,188 | 1,401,116 | 138,688 | ||||||||||||
Adjusted EBITDA (2) | $ | (278,545 | ) | $ | 663,179 | $ | (292,285 | ) | $ | 1,916,821 | ||||||
| (1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization. | ||||||||||||||||
| (2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges. | ||||||||||||||||
Adjusted EBITDA excluding other non-recurring costs (3) | ||||||||||||||||
Adjusted EBITDA | $ | (278,545 | ) | $ | 663,179 | $ | (292,285 | ) | $ | 1,916,821 | ||||||
Add: | ||||||||||||||||
Scaling and restructuring business growth costs | 12,708 | 0 | 82,185 | 11,676 | ||||||||||||
Offering costs | 106,593 | 0 | 106,593 | 0 | ||||||||||||
Acquisition costs | 56,558 | 113,436 | 274,362 | 171,515 | ||||||||||||
Adjusted EBITDA excluding other non-recurring costs (3) | $ | (102,686 | ) | $ | 776,615 | $ | 170,855 | $ | 2,100,012 | |||||||
| (3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs. | ||||||||||||||||
SOURCE: Cardiff Lexington Corporation
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Cardiff Lexington's third-quarter 2026 financial results?
Cardiff Lexington reported revenue of $1,912,179 and a net loss of $3,206,551 for the three months ended September 30, 2026. In the comparable 2025 quarter, revenue was $3,058,740 and net loss was $1,144,299.
What is the status of Cardiff Lexington's planned acquisition?
The planned acquisition has not reached a definitive agreement, and no definitive execution date has been established. Financing and equity term sheets have been accepted, but due diligence and negotiations continue. Cardiff anticipates further progress in December, subject to satisfactory due diligence and final financing arrangements.